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Urinary biomarkers, such as albumin and other markers
of kidney injury, are frequently reported as a normalized
ratio to urinary creatinine (UCr) concentration [UCr] to
control for variations in urine flow rate. The implicit
assumption is that UCr excretion is constant across and
within individuals, such that changes in the ratio will reflect
changes in biomarker excretion. Using computer simulations
of creatinine kinetics, we found that normalized levels of a
biomarker reflecting tubular injury can be influenced by
dynamic changes in the UCr excretion rate when the
glomerular filtration rate changes. Actual timed urine
collections from hospitalized patients with changing
glomerular filtration rates and/or critical illness exhibited
variability in UCr excretion rates across and within
individuals. Normalization by [UCr] may, therefore, result
in an underestimation or overestimation of the biomarker
excretion rate depending on the clinical context. Lower
creatinine excretion in the setting of acute kidney injury or
poor renal allograft function may amplify a tubular injury
biomarker signal, thereby increasing its clinical utility. The
variability of creatinine excretion, however, will complicate
the determination of a threshold value for normalized
biomarkers of acute or chronic kidney disease, including
albumin. Thus, we suggest that the most accurate method to
quantify biomarkers requires the collection of timed urine
specimens to estimate the actual excretion rate, provided
that the biomarker is stable over the period of collection.
This ideal must be balanced, however, against practical
considerations.
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Urinary biomarkers may provide sensitive and specific
diagnostic tools for the identification of acute kidney injury
(AKI). Urinary kidney injury molecule-1 (KIM-1), neutro-
phil gelatinase-associated lipocalin, N-acetyl-b-D-glucos-
aminidase, interleukin-18, L-type fatty acid-binding protein,
and a number of other markers are promising for early and
accurate diagnosis of AKI1–3 and for the prediction of clinical
outcomes.4–6
The kidney has the capacity to regulate water reabsorption
over more than an order of magnitude range; hence, the
urinary concentration of any putative biomarker is depen-
dent not only on the biomarker excretion rate but also on the
urinary flow rate. Owing to the effects of water reabsorption
on urinary solute concentrations, urinary biomarker con-
centrations are commonly expressed as a ratio to the urinary
creatinine (UCr) concentration—for example, albuminuria is
expressed as the albumin-to-creatinine ratio.7 The underlying
assumptions for this approach are that the UCr excretion
rate is constant within an individual over time and
across individuals, or that biomarker production or
excretion has a linear relationship with UCr excretion across
individuals. Although AKI biomarkers of tubular injury
are often normalized to urine creatinine,1–4,8–12 the assum-
ption of constant UCr excretion is not correct when renal
function is rapidly changing or when comparing across
individuals.
It is useful to consider the determinants of [UCr].
Creatinine is freely filtered at the glomerulus and secreted
by tubules to varying degrees;13 in the case of AKI, creatinine
may also backleak across the injured tubular epithelium back
into the systemic circulation.14 Therefore, the amount
excreted in the urine can be described as:
½SCrGFRþ TScrBcr¼ ½UCrUFR ð1Þ
where [SCr] is ‘serum creatinine concentration,’ GFR ‘glome-
rular filtration rate,’ TScr ‘tubular secretion rate of
creatinine,’ Bcr ‘backleak rate of creatinine,’ [UCr] ‘urinary
creatinine concentration,’ and UFR ‘urinary flow rate.’
Neglecting tubular secretion and backleak, [UCr] is inversely
proportional to UFR under steady-state conditions. As the
urinary concentration of any biomarker is also inversely
proportional to UFR for a given amount of total excreted
biomarker, normalizing to [UCr] under steady-state
or ig ina l a r t i c l e http://www.kidney-international.org
& 2010 International Society of Nephrology
Received 30 January 2010; revised 8 March 2010; accepted 30 March
2010; published online 16 June 2010
Correspondence: Sushrut S. Waikar, Renal Division, Brigham and Women’s
Hospital, MRB-4, 75 Francis Street, Boston, Massachusetts 02115, USA.
E-mail: swaikar@partners.org
486 Kidney International (2010) 78, 486–494
conditions accounts for variations in UFR, assuming no
effect of UFR on biomarker or creatinine excretion rate.
In at least four clinical settings, normalization to [UCr]
may be misleading for urinary biomarkers: when comparing
urinary biomarker excretion among individuals with (1)
different creatinine generation rates or extrarenal degradation
rates; (2) when GFR is changing and a steady state has not
yet been achieved; (3) when creatinine secretion differs; and
(4) when tubular backleak of creatinine differs.
These analyses were performed to explore the potential
biases introduced by normalization to [UCr] due to changes
in GFR both empirically in patients with or at risk of
AKI, and from a theoretical perspective using a computer
simulation of creatinine kinetics. We use the term creatinine
clearance (CrCl) to encompass changes in GFR and tubular
secretion and backleak of creatinine.
RESULTS
Simulations of AKI
To clarify the effects of changes in [UCr] alone on urinary
biomarker determinations, we first assumed that there is no
change in urinary biomarker excretion; we assumed an
arbitrary biomarker excretion rate of 60 ng/h, a urinary flow
rate of 0.6 dl/h, and an UCr excretion rate of 60mg/h. The
baseline concentration of the urinary biomarker is 60 ng/dl
(absolute) and 1 ng/mg creatinine (normalized). Figure 1
shows the effects of severe AKI (abrupt reduction in CrCl
from 100 to 10ml/min) on SCr and the normalized urinary
biomarker concentration, assuming no change in excretion of
the biomarker. (It is noteworthy that changes in the
biomarker concentration normalized to [UCr] are indepen-
dent of changes in urine output, assuming that the
concentrations of UCr and the biomarker are equally affected
by changes in urine output.) Immediately after severe AKI,
the UCr excretion rate decreases in proportion to the
magnitude of the decrease in CrCl, thereby abruptly
increasing the normalized biomarker level from 1 to 10 ng/
mg, despite a constant production and excretion rate of the
biomarker. If urine samples are collected 4, 12, and 24 h later,
the normalized urinary biomarker concentration remains
elevated at 6.7, 4.2, and 2.8 ng/mg, respectively. An apparent
50% increase in the urinary biomarker level (that is, from 1.0
to 1.5 ng/mg) is still present 74 h after initiation of severe AKI.
In the case of less severe AKI (abrupt reduction in CrCl
from 100 to 40ml/min), increases in SCr and UCr-normal-
ized biomarker concentrations are less pronounced but
nevertheless significant (Figure 2). The immediate increase
in the biomarker level to 2.5 ng/mg is again proportional to
the magnitude of the reduction in CrCl. At 4, 12, and 24 h
later, the normalized urinary biomarker concentration is 1.9,
1.4, and 1.2 ng/mg, respectively.
Recovery from AKI
Urinary biomarkers may be used to predict the duration of
AKI or the probability of recovery. Therefore, we simulated
recovery from severe AKI and the corresponding effects on a
normalized urinary biomarker, the production rate of which
does not change. Figure 3 shows results from a simulation in
which severe AKI (abrupt reduction in CrCl from 100 to
10ml/min) is followed 5 days later by recovery (linear
increase in CrCl from 10 to 100ml/min over 24 h). At the
time that recovery begins, the normalized urinary biomarker
levels decrease due to the increase in UCr excretion. Twelve
hours after recovery begins, the normalized urinary biomar-
ker concentration is 0.3 ng/mg, which is a 70% reduction
from baseline values. Forty-eight hours after recovery has
begun, the normalized urinary biomarker concentration
approaches baseline values as steady state is approached.
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Figure 1 |Change in serum creatinine concentration (gray)
and urine creatinine-normalized biomarker concentration
(black) after severe acute kidney injury (acute decrease in
creatinine clearance at time 0 from 100 to 10ml/min). The
urinary biomarker production and excretion rates are assumed
not to change; the effect on the normalized biomarker level is
due to changes in urinary creatinine excretion rate.
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Figure 2 |Change in serum creatinine concentration (gray)
and urine creatinine-normalized biomarker concentration
(black) after mild acute kidney injury (acute decrease in
creatinine clearance at time 0 from 100 to 40ml/min). The
urinary biomarker production and excretion rates are assumed
not to change; the effect on the normalized biomarker level is due
to changes in urinary creatinine excretion rate.
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Simulation of rapid recovery of renal function after kidney
transplantation
Immediately after kidney transplantation, the UCr excretion
rate increases in proportion to the increase in CrCl. The
effect on an UCr-normalized biomarker is opposite to that
seen after AKI and similar to that seen in recovery from AKI:
the greater the improvement in CrCl, the lower the apparent
normalized urinary biomarker level. Figure 4 shows changes
in biomarker concentration normalized to [UCr] in prompt
graft function (PGF), and delayed graft function (DGF). Estimates
for model parameters such as urinary flow rate, creatinine
clearance, and changes in volume of distribution in PGF and
DGF up to 72 h following transplantation were taken from
the physiological studies of Alejandro et al.15 In PGF, CrCl is
assumed to increase linearly from 30 to 60 ml/min over 72 h.
In DGF, CrCl is assumed to remain steady at 6ml/min. For
both, creatinine generation rate was set at 36mg/h
to approximate a pre-transplantation [SCr] of 10mg/dL;
urinary biomarker excretion was assumed to be 36 ng/h.
Volume of distribution increased by 2.1l in PGF and 4l for
DGF, accounting for the slight increase in the normalized
urinary biomarker concentration in DGF despite a constant
CrCl, in which CrCl increases from 10 to 12ml/min. Despite
equal excretion rates of a urinary biomarker, a patient with
DGF will appear to have a higher urinary biomarker level
than a patient with PGF in the first several hours after
transplantation. If urine samples are collected at 4 h after
transplant, a patient with DGF will have an UCr-normalized
biomarker concentration more than five times higher than
that of a patient with PGF (1.0 versus 0.2 ng/mg), despite
no actual change or difference in kidney production of
the biomarker. At 12 and 24 h after transplantation, the
urinary biomarker level remains higher in DGF than in
PGF (1.0 versus 0.3 ng/mg at 12 h; 1.0 versus 0.4 ng/mg
at 24 h).
Timed urine collections
A straightforward method to eliminate many of the
quantitative biases introduced by rapid changes in UCr is
to collect timed samples of urine. Timed urine collections
were performed in 12 kidney transplant recipients during the
immediate postoperative period and 24 patients admitted
to the intensive care unit. In 11 of the 24 intensive care
unit patients, serial daily collections were performed. As
shown in Table 1, extrapolated UCr excretion rates (assuming
constant excretion rate over a period of 24 h) in the post-
kidney transplant period varied substantially across patients,
ranging from 238mg/day in subject 6 (a recipient with DGF)
to 2327mg/day in subject 8 (a recipient with PGF). The low
[UCr] in the patient with DGF led to a nearly four-fold
higher urinary KIM-1/creatinine ratio (UKIM1/Cr) compared
with the 24 h extrapolated UKIM1 excretion rate, predictably
determined by the fact that UKIM1/Cr is in units of
nanogram KIM-1 per milligram of creatinine. Conversely,
in the patient with PGF, the high [UCr] led to a more than
two-fold lower [UKIM1/Cr] compared with the 24 h UKIM1
excretion rate. Substantial variability in extrapolated UCr
excretion rates was also observed among intensive care unit
patients (Table 2), ranging from 139mg/day in subject 13, a
22-year-old, 61 kg patient with cystic fibrosis and respiratory
failure, to 7198mg/day in subject 15, a 72-year-old, 110 kg
patient recovering from AKI. The comparisons between the
[UKIM1/Cr] and the extrapolated 24 h UKIM1 excretion rate
are also shown in Table 2. In Table 3, the results from
serial urine collections are shown for five intensive care
unit patients, three of whom had AKI and increasing SCr
during the course of collection. In the three patients with
AKI (subjects 27, 28, and 31), UCr excretion rates were
low (o700mg/day) but relatively constant over the collec-
tion period. By contrast, subject 26 showed a more than
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Figure 3 |Change in serum creatinine concentration (gray) and
urine creatinine-normalized biomarker concentration (black)
after severe acute kidney injury (acute decrease in creatinine
clearance at time 0 from 100 to 10ml/min, followed 5 days
later by a linear increase to 100ml/min over 24h (diagonal
arrow)). The urinary biomarker production and excretion rates are
assumed not to change; the effect on the normalized biomarker
level is due to changes in urinary creatinine excretion rate.
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Figure 4 |Changes in the urine creatinine-normalized
biomarker concentration after prompt graft function and
delayed graft function. The urinary biomarker production and
excretion rates are assumed not to change; the effect on the
normalized biomarker level is due to changes in urinary creatinine
excretion rate.
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Table 1 | Timed urine collections for creatinine and KIM-1 measurement from patients undergoing kidney transplantation
[SCr] (mg/dl)
Subject
Age (years)/
sex/race
Weight
(kg)
Original kidney disease,
type of transplant POD 0 POD 1 POD 2 POD 3
Renal
function
Duration of
collection (h),
volume (ml)
[UCr],
mg/ml
[UKIM1],
pg/ml
UCr
excretion
rate, mg/24 h
UKIM1
excretion
rate, lg/24 h
[UKIM1/Cr],
lg/g
1 54/M/C 68 Polycystic kidney disease,
LURT
9.1 6.8 5.2 3.7 PGF 4.75, 1000 0.32 79.1 1607 0.40 0.25
2 64/M/C 82 FSGS, LURT 5.6 3.5 1.9 1.7 PGF 6, 675 0.81 185 2198 0.50 0.23
3 25/F/C 42 Renal dysplasia, LRRT 4.2 2.3 0.9 0.8 PGF 6, 850 0.26 59.4 887 0.20 0.23
4 55/M/C 84 Diabetic nephropathy, LURT 9.4 5.3 5.0 4.8 SGF 6, 1450 0.19 180 1125 1.04 0.93
5 50/M/C 84 Polycystic kidney disease,
LURT
7.3 6.7 6.7 5.2 SGF 6, 1375 0.37 175 2046 0.96 0.47
6 65/F/AA 84 Diabetic nephropathy, LURT 10.3 8.5 9.3 9.2 DGF 6, 50 1.19 5075 238 1.02 4.26
7 47/F/C 57 IgA nephropathy, LURT 4.1 3.0 1.3 0.9 PGF 6, 475 0.57 965 1077 1.83 1.70
8 58/M/AA 79 Hypertension, LRRT 7.8 5.3 2.4 1.6 PGF 6, 2300 0.25 362 2327 3.33 1.43
9 55/M/C 107 Renal hypoplasia, LRRT 5.9 6.6 7.4 4.6 DGF 6, 300 0.36 834 431 1.00 2.32
10 43/F/C 72 Lupus nephritis, pre-emptive
LRRT
2.2 1.3 0.9 0.8 PGF 6, 1200 0.25 501 1176 2.40 2.04
11 63/F/C 72 Polycystic kidney disease,
LRRT
5.0 4.3 2.0 1.2 PGF 6, 775 0.60 147 1845 0.46 0.25
12 50/F/C 66 Hypertension, LURT 4.3 2.5 1.9 1.3 PGF 6, 300 1.46 4505 1746 5.41 3.10
Abbreviations: AA, African American; C, Caucasian; DGF, delayed graft function; FSGS, focal segmental glomerulosclerosis; KIM-1, kidney injury molecule-1; LRRT, living related
renal transplant; LURT, living unrelated renal transplant; POD, postoperative day; PGF, prompt graft function; SCr, serum creatinine; SGF, slow graft function; UCr, urinary
creatinine; UKIM1, urinary KIM-1; UKIM1/cr, urinary KIM-1/creatinine.
Date of urine sample collection is denoted by underlined serum creatinine concentration.
Table 2 | Timed urine collections for creatinine and KIM-1 measurement from patients admitted to the intensive care unit
SCr (mg/dl)
Subject
Age (years)/
sex/race
Wt
(kg) Clinical details Day-1 Day 0 Day 1 Day 2
AKI
diagnosis
Duration of
collection (h),
volume (ml)
[UCr],
mg/ml
[UKIM1],
pg/ml
UCr excretion
rate,
mg/24 h
UKIM1
excretion
rate, lg/24 h
[UKIM1/cr],
lg/g
13 22/F/C 61 Cystic fibrosis, s/p lung
transplant, admitted with
pneumonia and
respiratory failure
1.0 1.0 1.0 0.8 No AKI 4, 125 0.19 307 139 0.23 1.66
14 64//F/C 53 Tumor lysis syndrome
from AML blast crisis;
sepsis
1.0 0.9 0.9 — No AKI 4, 575 0.12 664 400 2.29 5.72
15 72/M/C 110 Sepsis syndrome from
Group B strep infection
of prosthetic knee
1.6 1.4 1.1 1.1 Recovering
from AKI
4, 700 1.71 268 7198 1.13 0.16
16 69/F/C 81 Myasthenia gravis crisis,
pyelonephritis
1.7 1.4 1.1 1.1 Recovering
from AKI
6, 275 0.83 1015 916 1.12 1.22
17 65/M/C 72 Burkitt’s lymphoma, AKI
from sepsis
2.5 1.9 1.9 1.9 Established
AKI
6, 1130 0.31 1926 1405 8.71 6.19
18 45/F/C 45 Metastatic breast cancer,
perforated duodenal
ulcer
0.5 0.6 0.6 0.6 No AKI 6, 575 0.20 186 469 0.43 0.91
19 79/M/C 67 Aspiration pneumonia
and sepsis after bowel
surgery
1.2 1.3 1.1 1.0 No AKI 6, 300 1.30 1093 1559 1.31 0.84
20 60/F/C 89 Metastatic endometrial
cancer, ventilatory failure,
and sepsis
0.6 0.6 — No AKI 6, 245 0.90 4793 886 4.70 5.30
21 21/M/A 68 Septic pulmonary emboli
from jugular vein
suppurative
thrombophlebitis
0.6 0.6 0.6 0.5 No AKI 6, 375 1.08 5938 1620 8.91 5.50
22 54/F/C 68 Post-op from bilateral
lung transplant for
idiopathic
pulmonary fibrosis
0.9 0.9 1.1 1.0 No AKI 6, 900 0.23 741 824 2.67 3.24
23 65/F/C 50 Chronic obstructive
pulmonary disease
exacerbation
0.6 0.6 0.7 0.9 No AKI 6, 1075 0.14 411 611 1.77 2.89
24 60/M/C 68 Respiratory failure from
acute interstitial
pneumonitis
0.5 0.7 0.6 1.2 AKI 6, 300 0.80 1953 961 2.34 2.43
25 75/F/C 113 Chronic obstructive
pulmonary disease
exacerbation
1.6 1.4 1.1 0.8 Recovering
from AKI
6, 550 0.58 2480 1283 5.46 4.25
Abbreviations: A, Asian; AKI, acute kidney injury; AML, acute myelogenous leukemia; C, Caucasian; KIM-1, kidney injury molecule-1; SCr, serum creatinine; UCr, urinary
creatinine; UKIM1, urinary KIM-1; UKIM1/cr, urinary KIM-1/creatinine.
Day 0 for serum creatinine measurement corresponds to the date of urine sample collection. (—) denotes date of death.
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Table 3 | Serial urine collections in patients admitted to the intensive care unit
Subject
Age (years)/
sex/ race
[SCr]
(mg/dl)
Duration of collection (h),
volume (ml)
[UCr],
mg/ml
[UKIM1],
pg/ml
UCr excretion
rate, mg/24h
UKIM1 excretion
rate, lg/24h
[UKIM1/Cr],
lg/g
26 71/M/C, subdural hematoma; weight 90 kg
Day 1 1.0 —
Day 0 0.8 6, 350 0.61 527 857 0.74 0.86
Day 1 0.7 6, 300 1.88 3028 2251 3.63 1.61
Day 2 0.6 6, 775 1.12 1580 3460 4.89 1.41
Day 3 0.7 6, 600 1.09 1111 2604 2.67 1.02
27 46/F/AA, cirrhosis, septic shock, AKI; weight 50 kg
Day 1 0.8 —
Day 0 1.2 4, 100 0.55 1765 328 1.06 3.23
Day 1 1.7 6, 150 0.44 1051 262 0.63 2.41
Day 2 2 6, 150 0.41 987 247 0.59 2.40
28 62/F/C, lung transplant recipient, hypoxemic respiratory failure, pneumonia, AKI; weight 58 kg
Day 1 1.6 —
Day 0 2.4 4, 80 1.09 1046 523 0.50 0.96
Day 1 2.6 5, 250 0.40 225 475 0.27 0.57
Day 2 3.3 4, 200 0.57 295 682 0.35 0.52
29 59/M/C; CLL, hypoxemic respiratory failure, pneumonia; weight 69 kg
Day 1 0.8 —
Day 0 0.8 6, 475 0.41 2440 771 4.63 6.01
Day 1 0.8 4, 1050 0.15 1091 945 6.87 7.27
30 56/M/C, morbid obesity, postoperative from surgical revision of gastric bypass; weight 158 kg
Day 1 0.8 —
Day 0 0.7 6, 275 1.68 3636 1844 4.0 2.17
Day 1 0.7 6, 375 1.41 2282 2112 3.4 1.62
31 48/M/C; myelodysplastic syndrome, hypoxemic respiratory failure, pneumonia, sepsis; weight 82 kg
Day 1 1.1 —
Day 0 1.8 6, 450 0.10 3258 175 5.87 33.59
Day 1 2.2 6, 100 0.08 4607 32 1.84 57.58
Day 2 2.8 6, 20 0.06 6620 5 0.53 106.78
32 69/F/C; hypoxemic respiratory failure and septic shock; weight 58 kg
Day 1 0.6 —
Day 0 0.8 6, 315 0.56 2174 702 2.74 3.90
Day 1 0.7 4, 150 0.49 1246 442 1.12 2.54
Day 2 0.8 6, 310 0.50 2954 615 3.66 5.95
33 75/F/C; NSTEMI, hypoxemic and hypercarbic respiratory failure; weight 76 kg
Day 1 1.0 —
Day 0 0.9 5, 550 0.42 413 1106 1.09 0.99
Day 1 1.2 6, 400 0.83 941 1333 1.51 1.13
34 64/F/AA; cardiac arrest from ventricular fibrillation from unclear cause, also anoxic brain injury; weight 145 kg
Day 1 1.6 —
Day 0 1.2 6, 400 0.61 1814 974 2.90 2.98
Day 1 1.2 6, 275 0.99 1095 1087 1.20 1.11
35 48/F/C; cardiopulmonary arrest after choking on foreign object; weight 60 kg
Day 1 0.7
Day 0 0.7 6, 410 0.61 2547 1005 4.18 4.16
Day 1 0.7 6, 775 0.38 879 1187 2.72 2.29
Day 2 0.7 6, 950 0.35 329 1326 1.24 0.94
Day 3 0.6 6, 350 0.78 784 1089 1.10 1.01
36 61/M/C; small bowel resection for obstruction, also TTP with renal failure; weight 86 kg
Day 1 4.4 —
Day 0 3.6 6, 20 1.77 4961 141 0.40 2.81
Day 1 3.7 5, 30 1.24 13,824 179 1.66 11.11
Day 2 3.8 6, 175 1.18 10,400 823 7.28 8.84
Abbreviations: AA, African American; AKI, acute kidney injury; C, Caucasian; CLL, chronic lymphocytic leukemia; NSTEMI, non-ST-elevation myocardial infarction; SCr, serum
creatinine; TTP, thrombotic thrombocytopenic purpura; UCr, urinary creatinine; UKIM1, urinary KIM-1; UKIM1/cr, urinary KIM-1/creatinine.
Daily urine sample collection began on day 0.
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three-fold increase in UCr excretion over a 4-day period,
over which time the SCr level decreased from 1.0 to a nadir
of 0.6mg/dl. The comparisons between the UKIM1/Cr and
the extrapolated 24 h UKIM1 excretion rate are shown
graphically in Figure 5.
DISCUSSION
We have addressed quantitatively the implications of using
UCr to normalize urinary biomarker levels. The pitfalls of
reporting absolute concentrations of a urinary biomarker are
easy to appreciate: oliguria will cause an increase, and
polyuria a decrease, in the absolute concentration of a
biomarker, the production and excretion rates of which
are constant. Normalizing a urinary biomarker concentration
to UCr takes into account differences in urinary flow rate.
However, when normalizing, one must also take into
consideration the other determinant of [UCr]: the rate of
creatinine excretion by the kidney. Under nonsteady-state
conditions such as AKI and kidney transplantation, the
UCr excretion rate changes over time; unless the biomarker
under consideration behaves exactly like creatinine (that is,
filtered, secreted to some extent, not normally reabsorbed),
the normalized level will be affected by differences in
UCr excretion. The phenomena depicted in our simula-
tion studies were supported by the results obtained from
timed urine samples in patients with AKI and ˇafter
kidney transplantation. Furthermore, baseline levels of UCr
excretion may vary considerably across individuals, as
demonstrated in our timed samples obtained from patients
with stable SCr.
The implicit assumptions underlying the practice of
reporting ‘normalized’ urinary biomarkers deserve to
be highlighted. Assuming that the UCr excretion rate in
healthy individuals is B1 g/day, the ratio between a urinary
biomarker and the [UCr] is considered clinically to
approximate the 24 h excretion rate of the biomarker
(in this example, ng/day).16 UCr excretion is in fact not
uniformly 1 g/day across individuals and even within
the same individual over time. Dynamic changes in UCr
excretion and baseline differences in UCr excretion—as
demonstrated in our timed samples—will proportionally
influence the normalized level of a urinary biomarker even if
the actual biomarker excretion rate (per 24 h or any unit of
time) is unchanged. It is worthwhile to consider how
normalization may complicate the interpretation of urinary
biomarker levels under steady-state conditions (for example,
when comparing levels in those with stable SCr levels) and
under nonsteady-state conditions (for example, in AKI and
after kidney transplantation).
In the steady state, UCr excretion is constant but may
differ from one individual to the next. Unless the expected
normal biomarker excretion rate is assumed to be linearly
related to the UCr excretion rate (for example, if it is a proxy
for renal mass), differences in UCr excretion will bias the
normalized level of a urinary biomarker. For example, if
two individuals each have a normalized biomarker level
of 1 ng/mg, but one excretes 500mg and the other 2000mg of
creatinine per day, the actual extrapolated biomarker
excretion rate will be 0.5 and 2.0 ng/day, respectively. The
critical issue in this instance is which determination is more
believable: do the two individuals differ by fourfold (as would
be predicted by a 24-h timed collection) or are they
equivalent (as predicted by the normalized value) in whatever
biological process is being estimated by the biomarker? The
answer to this question may vary depending on the
biomarker tested and the population in which it is being
tested. For the purpose of comparing urinary biomarker
levels in children versus adults, for example, normalization to
[UCr] may be reasonable, if biomarker excretion capacity is
believed to have some linear relationship with body size
(which in turn has a rough relationship with UCr excretion
rate). However, when comparing adults, the answer may not
be as straightforward. UCr excretion is variable across
individuals and even within the same individual. For
example, African Americans have generally higher SCr levels
than do Whites across the spectrum of kidney disease,17,18
believed to be due to differences in creatinine generation rate,
and therefore higher UCr excretion rates. In addition,
patients with chronic kidney disease (CKD) have lower rates
of UCr excretion than do those without CKD,19 and
creatinine excretion rates may decline during progression of
kidney disease,20 due to an increase in extrarenal degradation
of creatinine. Furthermore, UCr excretion also shows within-
person variability, with estimates for intra-individual coeffi-
cients of variation (CVs) for repeated 24 h urine collections
ranging from 10.5 to 14.4%.21,22 Other studies have also
suggested diurnal variation in creatinine excretion and/or
variability hour to hour and day to day.21,23–27 One study28 of
12 individuals (including the authors of the study), admitted
to a research ward for six 24 h urine collections, demon-
strated intra-individual CVs ranging from 3.7 to 14.3% for
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Figure 5 |Graphical comparison of extrapolated 24h urinary
KIM-1 excretion rate (y axis) versus normalized urinary KIM-1/
creatinine ratio. The solid diagonal line represents the line of
identity. Three outlier measurements from subject #31 are
excluded (see Table 3). KIM-1, kidney injury molecule-1.
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24 h collections, and 9.4–27.1% for 4- and 8-h collections.
(A 10% CV around a mean of 1 g/day corresponds to
95% confidence interval of 804–1196mg/day, whereas a
20% CV corresponds to a 95% confidence interval of
608–1392mg/day.)
Even the interpretation of urinary albumin:creatinine
concentration may be confounded by inter-individual
differences in creatinine generation rate: although a small
amount of albumin may be filtered by the glomerulus, its
metabolism in the tubules differs from that of creatinine (that
is, albumin is catabolized, whereas creatinine is secreted), and
its plasma levels do not depend mainly on kidney excretion
as is the case for creatinine.29 Cirillo et al.30 reported that
high urinary albumin:creatinine ratio in individuals with
low muscle mass more commonly indicates low UCr
excretion rather than true microalbuminuria and cardiovas-
cular disease. Even in the case of filtered biomarkers (such as
the toxin 1-hydroxypyrene, for which creatinine normal-
ization has been argued to be valid31), differences in tubular
secretion of creatinine across individuals may confound
comparisons of normalized biomarker levels.
Under nonsteady-state conditions, the differences in UCr
excretion can be even more marked, as shown in our timed
collections in patients with AKI and after kidney transplanta-
tion. The extrapolated UCr excretion rates ranged from
under 100mg/day in a patient with oliguric AKI from septic
shock to more than 7000mg/day in a patient recovering
from AKI. Among the kidney transplant recipients, the
extrapolated UCr excretion rates ranged from under
300mg/day in a patient with DGF to more than
2100mg/day in a patient with PGF. Extremely low [UCr],
such as the measurement of 0.06mg/mL in subject #31, may
arise from significant tubular backleak and result in a
distortion of normalized biomarker levels.
Limitations of our simulation studies include the use of
constant creatinine generation rates across individuals and
not modeling tubular secretion of creatinine or its backleak
across the injured tubular epithelium. To model creatinine
handling more precisely would require knowledge of
extrarenal degradation rate (which can be substantial in
CKD32), generation rate (which likely varies in CKD and
acute illness33), rate of tubular secretion (which increases
proportionally as GFR decreases34 and which may be
impaired in the posttransplanted ischemic allograft35), and
the rate of tubular backleak of creatinine in the case of
ischemic injury. Values for these parameters may vary from
one individual to another and in different clinical states.
Nevertheless, simulation studies have provided a depiction of
the dynamic changes in UCr excretion due to changing CrCl,
and how those changes in [UCr] can influence the normal-
ized level of a urinary biomarker. Our urine sample collection
in hospitalized individuals was performed from indwelling
urinary catheters, thereby limiting errors in collecting the
entirety of the urine sample. Although some urine in the
tubing may have been inadvertently omitted from the timed
collection, the inaccuracies are unlikely to be large enough to
qualitatively affect our results, which demonstrate a wide
range in UCr excretion rates.
A single normalized urinary biomarker measurement
from an individual needs to be seen as a point estimate of
a range of probable values for the actual excretion rate. The
range derives not just from analytical variability in biomarker
measurement and biological variability in biomarker produc-
tion and excretion but also from variability in creatinine
excretion rate, which can be substantial. If it was possible to
accurately predict UCr excretion rates based on clinical
variables such as age, weight, sex, and race, then creatinine-
normalized biomarker values could be appropriately ad-
justed. This area deserves further investigation. In critically ill
patients and in those expected not to be in the steady state,
dynamic changes in creatinine excretion are superimposed
upon baseline differences. Therefore, it may be useful to
examine changes in normalized biomarker levels compared
with baseline, to account for inter-individual differences in
baseline UCr excretion rates. Dynamic changes within
individuals may still affect the normalized values due to
changes in CrCl. On the basis of our results, we suggest that a
reasonable minimum threshold for validation in AKI studies
may be a two-fold change from baseline in normalized
biomarker values: lower changes from baseline may arise
from dynamic changes in UCr excretion, particularly if
samples are obtained during the early period when GFR is
changing rapidly.
We have confirmed that the implicit assumption of
constant UCr excretion is deeply flawed in hospitalized
individuals. We have demonstrated marked variability across
and within individuals in the settings of AKI, kidney
transplantation, and critical illness. In some clinical settings,
the effect of the denominator ([UCr]) on normalized
biomarker levels may serve the clinically useful purpose of
amplifying the signal of an injury biomarker: in AKI and
DGF, for example, the normalized ratio increases as [UCr]
decreases. As the concentrations of urinary biomarkers of
injury and [UCr] are expected to move in opposite directions
in renal recovery and renal injury, the normalized ratio does
have the potentially added benefit of amplifying a biomarker
signal. However, in hospitalized individuals, particularly in
the determination of reference ranges in critically ill patients
with and without kidney injury, timed collections would
seem to be justified on the basis of the considerations
presented in this study. Another reasonable approach would
be normalizing to the observed urinary flow rate at the time
of collection to determine the biomarker excretion rate.
How, then, should investigators and clinicians report and
interpret the levels of kidney injury biomarkers? Absolute
concentrations may be misleading because of differences in
urinary flow rate, whereas creatinine normalization may be
misleading because of differences in UCr excretion rate.
Timed collections—as performed in this study—provide an
estimate of biomarker excretion rate, which is probably the
most comparable value from one individual to the next, or
over time within an individual, if the biomarker under
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investigation is known to be stable over the time period of
collection (as has been shown for KIM-136 and creatinine37).
There are obvious practical limitations to timed collections,
however, especially in the ambulatory setting. However, in
biomarker studies of CKD, investigators should consider the
possible effect of decreased UCr excretion if normalized
biomarker levels are found to be higher in those with more
advanced CKD.
In conclusion, investigators should consider that normal-
ized values of urinary biomarkers may be profoundly affected
by variability in UCr excretion rates. In some scenarios,
normalization may amplify the signal of a biomarker,
potentially enhancing its utility as a diagnostic tool. In
others, spurious and misleading interpretations may develop
from an uncritical acceptance of a normalized value.
MATERIALS AND METHODS
Simulation studies
According to basic mass balance principles, the change in the
amount of creatinine in the body over time Dt is equal to the
amount of creatinine generated over time Dt minus the amount of
creatinine excreted over time Dt. Let G be the generation rate of
creatinine; C, the serum creatinine concentration; V, the volume
of distribution of creatinine; and K, creatinine clearance. (For
simplicity, we have omitted tubular secretion of creatinine,
extrarenal degradation of creatinine, and possible backleak of
creatinine across the injured tubular epithelium.) In a single
compartment model, as Dt approaches 0, the following differential
equation can be written:
dðCVÞ=dt ¼ G KC
Applying the product rule:
ðVdC=dtÞ þ ðCdV=dtÞ ¼ G KC
Rearranging this equation:
dC=dt ¼ ½G KC ðCdV=dtÞ=V ð2Þ
The creatinine excretion rate (KC) divided by the urinary flow
rate is equal to the instantaneous UCr concentration at any time t.
To investigate the effect of normalizing urinary biomarker
concentrations to [UCr], we assumed the null hypothesis—that is,
that a theoretical biomarker was excreted at a constant rate,
irrespective of CrCl, urinary flow rate, or the development of AKI.
The biomarker excretion rate divided by the urinary flow rate is
equal to the urinary biomarker concentration. Dividing the urinary
biomarker concentration by [UCr] is the ‘normalized’ urinary
concentration of the urinary biomarker, which is not affected by the
urinary flow rate.
We used the software packages Matlab and Simulink (The
Mathworks, Natick MA, USA), a graphical environment that enables
simulation of time-varying systems. The simulations permitted
independent adjustment of all of the determinants of serum and
urinary creatinine concentrations: clearance rate, volume of
distribution and its change over time, generation rate, and urinary
flow rate. With this simulation, we were able to investigate the
effects of normalizing or not normalizing the urinary concentration
of a secreted biomarker in simulations of changing CrCl, volume of
distribution, and urinary flow rate. We used a variable step
continuous solver using the fourth-order integration technique of
Runge–Kutta to simulate creatinine kinetics. The maximum step size
was set at 6min. We confirmed that the model simulated in
Simulink produced identical results for serum creatinine (to the
fourth decimal place) compared with directly calculated values from
the solution of differential equation (2), assuming no change in
volume of distribution: C(t)¼G/Kþ [C0G/K] eKt/V.
Timed urine collections in hospitalized patients
Timed urine samples were obtained from hospitalized patients with
indwelling Foley catheters. Individuals provided written informed
consent, and the protocol was approved by the BWH (Brigham and
Women’s Hospital) Institutional Review Board. For each collection,
the Foley catheter and tubing was emptied of urine before the timed
collection. At the end of the timed collection, the entire volume of
urine in the Foley catheter and tubing was drained. The volume of
collected urine was noted and an aliquot from the entire volume was
obtained for biomarker analyses. Urine samples were centrifuged at
3200 r.p.m. and the supernatant was stored at 801C in 1.8ml
Eppendorf tubes. Within 3 months of collection, urine samples were
thawed, vortexed, and centrifuged at 14,000 r.p.m. at 41C and
30–100ml of the supernatant was pipetted for biomarker measure-
ments. UCr was measured in the BWH clinical laboratory by the
Jaffe assay using the Roche/Hitachi Cobas C system (Roche
Diagnostics, Indianapolis, IN, USA). Urinary KIM-1 concentration
was measured using a microbead assay as described previously.38 For
each timed collection, we calculated the extrapolated 24 h excretion
rate of creatinine and KIM-1 (concentration volume 24 h/time
of collection), as well as the creatinine-normalized KIM-1
concentration (KIM-1 concentration/urine creatinine concentra-
tion). AKI was defined as a X50% increase in SCr over baseline or
admission values. DGF was defined as a o10% decrease in SCr per
day for the first 3 days after transplantation. PGF was defined as a
450% decrease in SCr within 3 days after transplantation. SGF was
defined as a o50% decrease in SCr within 3 days after
transplantation, excluding those who met the criteria for DGF.
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